Journal
CLINICAL AND LABORATORY HAEMATOLOGY
Volume 22, Issue 2, Pages 111-113Publisher
BLACKWELL SCIENCE LTD
DOI: 10.1046/j.1365-2257.2000.00283.x
Keywords
cladribine (2-chlorodeoxyadenosine, 2-CdA); hairy cell leukaemia; skin rash
Categories
Ask authors/readers for more resources
Although hairy cell leukaemia was first described 40 years ago, it is only in the last decade that newer therapeutic agents have enabled effective treatment. The purine nucleoside analogue, 2-chlorodeoxyadenosine (2-CdA) is currently considered as first-line therapy with a very high rate of complete remission. Although adverse events with 2-CdA are increasingly recognized, severe cutaneous reactions have been reported rarely. We describe two consecutive patients treated with 2-CdA for hairy cell leukaemia who both suffered extremely severe cutaneous reactions, one of which was life-threatening.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available